<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected pharmacokinetic characteristics of the echinocandins in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected pharmacokinetic characteristics of the echinocandins in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected pharmacokinetic characteristics of the echinocandins in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Variable</td> <td class="subtitle1">Caspofungin</td> <td class="subtitle1">Micafungin</td> <td class="subtitle1">Anidulafungin</td> </tr> <tr> <td>Elimination half-life adult* (hours)</td> <td>27 to 50</td> <td>14 to 17.2</td> <td>40 to 50</td> </tr> <tr> <td>Metabolism</td> <td>Hepatic: slow peptide hydrolysis and N-acetylation, with some spontaneous degradation to peptide product</td> <td>Hepatic: catechol-O-methyltransferase (COMT) and to a lesser extent, CYP1A2, 2B6, 2C, and 3A4</td> <td>Not metabolized: undergoes slow spontaneous degradation to inactive metabolites</td> </tr> <tr> <td>Dose adjustment for hepatic insufficiency</td> <td>Although manufacturer's labeling recommends a maintenance dose reduction of 50% for moderate hepatic insufficiency, pharmacokinetic data support use of full doses (ie, no adjustment) in all degrees of hepatic impairment to avoid subtherapeutic concentrations.<sup>[1]</sup></td> <td> <ul> <li>Mild and Moderate (Child-Pugh 5 to 9): none</li> <li>Severe (Child-Pugh &gt;9): no data</li> </ul> </td> <td>Not necessary</td> </tr> <tr> <td>Dose adjustment for renal insufficiency</td> <td>Not necessary</td> <td>Not necessary</td> <td>Not necessary</td> </tr> <tr> <td>Drug interactions<sup>¶</sup></td> <td> <ul> <li>Cyclosporine can increase caspofungin AUC; elevated hepatic transaminases also observed with this combination.</li> <li>Inducers of drug metabolism (eg, rifampin, efavirenz, nevirapine, phenytoin, dexamethasone, carbamazepine) can reduce caspofungin AUC and may cause subtherapeutic serum concentrations. Adjustment of therapy may be warranted.</li> </ul> </td> <td>N/A<sup>¶</sup></td> <td>N/A<sup>¶</sup></td> </tr> <tr> <td>CSF penetration (% of plasma)</td> <td>&lt;0.1</td> <td>&lt;0.1</td> <td>&lt;0.1</td> </tr> <tr> <td>Urinary excretion of unchanged drug (%)</td> <td>Approximately 1</td> <td>0.7</td> <td>&lt;1</td> </tr> <tr> <td>Protein binding (%)</td> <td>96 to 97</td> <td>99.8</td> <td>99</td> </tr> <tr> <td>Vd (L/kg)</td> <td>0.14</td> <td>0.39 +/– 0.11</td> <td>0.50</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>AUC: area under time versus concentration curve; CYP: cytochrome P; N/A: not applicable; CSF: cerebrospinal fluid; Vd: volume of distribution.</p>
<p>* Half-life of caspofungin and micafungin may be reduced in young children and infants compared with adults due to more rapid clearance.</p>
¶ This is not a complete list. For additional interactions, refer to the appropriate UpToDate clinical topics and <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program included with UpToDate.</div><div class="graphic_reference">Data from:
<ol>
<li>US Food and Drug Administration-approved product information.</li>
<li>Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739.</li>
<li>Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815.</li>
<li>Dodds Ashley E, Lewis R, Lewis J, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl 1:S28.</li>
<li>Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacotherapy 2009; 43:1647.</li>
<li>Lexicomp Online. Copyright ©1978-2023 Lexicomp, Inc. All Rights Reserved.</li>
</ol>
<p class="extra_spacing_top">Reference:</p>
<ol>
<li>Gustot T, Ter Heine R, Brauns E, et al. Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. J Antimicrob Chemother 2018; 73:2493.</li>
</ol></div><div id="graphicVersion">Graphic 56212 Version 22.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
